Cargando…

Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for an ever-increasing number of cancers. However, their use has also led to the emergence of immune-related adverse events, such as ICI-induced inflammatory arthritis. A reproducible, reliable, and accessible mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Subedi, Ananta, Williams, Sandra G., Yao, Lawrence, Maharjan, Suresh, Strauss, Julius, Sharon, Elad, Thomas, Anish, Apolo, Andrea B., Gourh, Pravitt, Hasni, Sarfaraz A., Gulley, James L., Kaplan, Mariana J., Katz, James D., Gupta, Sarthak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137682/
https://www.ncbi.nlm.nih.gov/pubmed/32101306
http://dx.doi.org/10.1001/jamanetworkopen.2020.0032
_version_ 1783518460950609920
author Subedi, Ananta
Williams, Sandra G.
Yao, Lawrence
Maharjan, Suresh
Strauss, Julius
Sharon, Elad
Thomas, Anish
Apolo, Andrea B.
Gourh, Pravitt
Hasni, Sarfaraz A.
Gulley, James L.
Kaplan, Mariana J.
Katz, James D.
Gupta, Sarthak
author_facet Subedi, Ananta
Williams, Sandra G.
Yao, Lawrence
Maharjan, Suresh
Strauss, Julius
Sharon, Elad
Thomas, Anish
Apolo, Andrea B.
Gourh, Pravitt
Hasni, Sarfaraz A.
Gulley, James L.
Kaplan, Mariana J.
Katz, James D.
Gupta, Sarthak
author_sort Subedi, Ananta
collection PubMed
description IMPORTANCE: Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for an ever-increasing number of cancers. However, their use has also led to the emergence of immune-related adverse events, such as ICI-induced inflammatory arthritis. A reproducible, reliable, and accessible modality is needed to assess and distinguish early ICI-induced inflammatory arthritis and help in management. Magnetic resonance imaging (MRI) of joints may be helpful for early diagnosis, guiding therapeutic decision-making, and identifying patients at high risk for erosive disease. OBJECTIVE: To assess the role of MRI of joints in patients with ICI-induced inflammatory arthritis. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series included patients enrolled at the National Institutes of Health Clinical Center in Bethesda, Maryland. Patients were evaluated by the rheumatology consultation service between December 27, 2016, and May 28, 2019. A retrospective health record review was performed to determine demographic characteristics, clinical characteristics of inflammatory arthritis and malignant tumors, and imaging findings. Inclusion criteria were patients who were enrolled on various institutional review board–approved protocols of ICIs, developed joint-related symptoms, and had MRI data for at least 1 joint. Data were analyzed from June 1, 2019, to September 1, 2019. EXPOSURES: Undergoing MRI of at least 1 joint. MAIN OUTCOMES AND MEASURES: All MRIs were reviewed for synovitis, tenosynovitis, bone marrow edema, and soft tissue conditions. RESULTS: A total of 8 patients (mean [SD] age, 58.8 [5.2] years; 6 women and 2 men) between the ages of 50 and 65 years who were undergoing ICI therapy for a variety of malignant tumors were included in this study. Only 1 patient was receiving combined ICI therapy. The results of 13 separate MRI examinations were reviewed. The most commonly performed MRIs were of the hands and wrists (9 MRIs), followed by knee examinations (3 MRIs). Tenosynovitis and synovitis were frequently seen in the hands and wrists. Bone marrow edema and erosions were also found in 3 patients, suggesting early damage. In larger joints (ie, knees and ankles), joint effusions and synovial thickening were characteristic. Most patients (5 patients) were treated with corticosteroids and had good responses. In patients with high-risk features on MRI imaging (eg, bone marrow edema, erosions), disease-modifying antirheumatic drug therapy was also discussed as a treatment option. CONCLUSIONS AND RELEVANCE: These findings suggest that advanced imaging may help to distinguish ICI-induced inflammatory arthritis from other causes of joint pain, aid in identifying patients at increased risk of joint damage, and provide utility in monitoring inflammatory arthritis treatment response in patients receiving ICI therapy.
format Online
Article
Text
id pubmed-7137682
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-71376822020-04-08 Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis Subedi, Ananta Williams, Sandra G. Yao, Lawrence Maharjan, Suresh Strauss, Julius Sharon, Elad Thomas, Anish Apolo, Andrea B. Gourh, Pravitt Hasni, Sarfaraz A. Gulley, James L. Kaplan, Mariana J. Katz, James D. Gupta, Sarthak JAMA Netw Open Original Investigation IMPORTANCE: Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for an ever-increasing number of cancers. However, their use has also led to the emergence of immune-related adverse events, such as ICI-induced inflammatory arthritis. A reproducible, reliable, and accessible modality is needed to assess and distinguish early ICI-induced inflammatory arthritis and help in management. Magnetic resonance imaging (MRI) of joints may be helpful for early diagnosis, guiding therapeutic decision-making, and identifying patients at high risk for erosive disease. OBJECTIVE: To assess the role of MRI of joints in patients with ICI-induced inflammatory arthritis. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series included patients enrolled at the National Institutes of Health Clinical Center in Bethesda, Maryland. Patients were evaluated by the rheumatology consultation service between December 27, 2016, and May 28, 2019. A retrospective health record review was performed to determine demographic characteristics, clinical characteristics of inflammatory arthritis and malignant tumors, and imaging findings. Inclusion criteria were patients who were enrolled on various institutional review board–approved protocols of ICIs, developed joint-related symptoms, and had MRI data for at least 1 joint. Data were analyzed from June 1, 2019, to September 1, 2019. EXPOSURES: Undergoing MRI of at least 1 joint. MAIN OUTCOMES AND MEASURES: All MRIs were reviewed for synovitis, tenosynovitis, bone marrow edema, and soft tissue conditions. RESULTS: A total of 8 patients (mean [SD] age, 58.8 [5.2] years; 6 women and 2 men) between the ages of 50 and 65 years who were undergoing ICI therapy for a variety of malignant tumors were included in this study. Only 1 patient was receiving combined ICI therapy. The results of 13 separate MRI examinations were reviewed. The most commonly performed MRIs were of the hands and wrists (9 MRIs), followed by knee examinations (3 MRIs). Tenosynovitis and synovitis were frequently seen in the hands and wrists. Bone marrow edema and erosions were also found in 3 patients, suggesting early damage. In larger joints (ie, knees and ankles), joint effusions and synovial thickening were characteristic. Most patients (5 patients) were treated with corticosteroids and had good responses. In patients with high-risk features on MRI imaging (eg, bone marrow edema, erosions), disease-modifying antirheumatic drug therapy was also discussed as a treatment option. CONCLUSIONS AND RELEVANCE: These findings suggest that advanced imaging may help to distinguish ICI-induced inflammatory arthritis from other causes of joint pain, aid in identifying patients at increased risk of joint damage, and provide utility in monitoring inflammatory arthritis treatment response in patients receiving ICI therapy. American Medical Association 2020-02-26 /pmc/articles/PMC7137682/ /pubmed/32101306 http://dx.doi.org/10.1001/jamanetworkopen.2020.0032 Text en Copyright 2020 Subedi A et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Subedi, Ananta
Williams, Sandra G.
Yao, Lawrence
Maharjan, Suresh
Strauss, Julius
Sharon, Elad
Thomas, Anish
Apolo, Andrea B.
Gourh, Pravitt
Hasni, Sarfaraz A.
Gulley, James L.
Kaplan, Mariana J.
Katz, James D.
Gupta, Sarthak
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title_full Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title_fullStr Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title_full_unstemmed Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title_short Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
title_sort use of magnetic resonance imaging to identify immune checkpoint inhibitor–induced inflammatory arthritis
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137682/
https://www.ncbi.nlm.nih.gov/pubmed/32101306
http://dx.doi.org/10.1001/jamanetworkopen.2020.0032
work_keys_str_mv AT subediananta useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT williamssandrag useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT yaolawrence useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT maharjansuresh useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT straussjulius useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT sharonelad useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT thomasanish useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT apoloandreab useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT gourhpravitt useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT hasnisarfaraza useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT gulleyjamesl useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT kaplanmarianaj useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT katzjamesd useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis
AT guptasarthak useofmagneticresonanceimagingtoidentifyimmunecheckpointinhibitorinducedinflammatoryarthritis